GT Biopharma Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for GTBP, updated each market day.
GTBP AI Sentiment
AI predicts GT Biopharma Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About GT Biopharma Inc. Common Stock
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Sector
Exchange
Market Cap
$13,514,798
Cap Tier
Employees
1
Headquarters
SAN FRANCISCO, CA
Listed Since
Feb. 11, 2021
Website
GTBP Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GTBP Volatility
GT Biopharma Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
